國立高雄大學圖資館 |

Language: English

Back

The future of HIV-1 therapeuticsresi...

Goodsell, David S.

The future of HIV-1 therapeuticsresistance is futile? /

Record Type:	Electronic resources : Monograph/item
Title/Author:	The future of HIV-1 therapeuticsedited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman.
Reminder of title:	resistance is futile? /
other author:	Torbett, Bruce E.
Published:	Cham :Springer International Publishing :2015.
Description:	x, 254 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Antiviral agents.
Online resource:	http://dx.doi.org/10.1007/978-3-319-18518-7
ISBN:	9783319185187 (electronic bk.)

The future of HIV-1 therapeuticsresistance is futile? /
The future of HIV-1 therapeuticsresistance is futile? /[electronic resource] :edited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman. - Cham :Springer International Publishing :2015. - x, 254 p. :ill., digital ;24 cm. - Current topics in microbiology and immunology,v.3890070-217X ;. - Current topics in microbiology and immunology ;v.351..

HIV Therapy Looking Towards the Future -- Computational challenges of structure-based approaches applied to HIV -- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 -- HIV-1 integrase multimerization as a therapeutic target -- Targeting HIV transcription: The quest for a functional cure -- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder -- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy -- The Triple Threat of HIV-1 Protease Inhibitors -- Illustrations of the HIV Life Cycle.

This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.

ISBN: 9783319185187 (electronic bk.)

Standard No.: 10.1007/978-3-319-18518-7doiSubjects--Topical Terms:

229449
Antiviral agents.

LC Class. No.: RA643.8

Dewey Class. No.: 614.599392

The future of HIV-1 therapeuticsresistance is futile? /
LDR:02336nmm a2200325 a 4500 001 465413
003 DE-He213
005 20151104161937.0
006 m d
007 cr nn 008maaau
008 151222s2015 gw s 0 eng d
020 $a 9783319185187 (electronic bk.)
020 $a 9783319185170 (paper)
024 7 $a 10.1007/978-3-319-18518-7 $2 doi
035 $a 978-3-319-18518-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RA643.8
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 614.599392 $2 23
090 $a RA643.8 $b .F996 2015
245 0 4 $a The future of HIV-1 therapeutics $h [electronic resource] : $b resistance is futile? / $c edited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a x, 254 p. : $b ill., digital ; $c 24 cm.
490 1 $a Current topics in microbiology and immunology, $x 0070-217X ; $v v.389
505 0 $a HIV Therapy Looking Towards the Future -- Computational challenges of structure-based approaches applied to HIV -- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 -- HIV-1 integrase multimerization as a therapeutic target -- Targeting HIV transcription: The quest for a functional cure -- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder -- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy -- The Triple Threat of HIV-1 Protease Inhibitors -- Illustrations of the HIV Life Cycle.
520 $a This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.
650 0 $a Antiviral agents. $3 229449
650 0 $a HIV infections $x Prevention. $3 534505
650 0 $a HIV antibodies. $3 719126
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Drug Resistance. $3 338425
650 2 4 $a Virology. $3 196498
650 2 4 $a Infectious Diseases. $3 274275
700 1 $a Torbett, Bruce E. $3 719125
700 1 $a Goodsell, David S. $3 194432
700 1 $a Richman, Douglas D. $3 587862
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Current topics in microbiology and immunology ; $v v.351. $3 557512
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-18518-7
950 $a Biomedical and Life Sciences (Springer-11642)